{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:43:42Z","timestamp":1791323022981,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00415-018-8893-9","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T04:25:10Z","timestamp":1525753510000},"page":"1618-1624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study"],"prefix":"10.1007","volume":"265","author":[{"given":"Carlo","family":"Wilke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie N.","family":"Hayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"8893_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1212\/WNL.0000000000004311","volume":"89","author":"I Giordano","year":"2017","unstructured":"Giordano I, Harmuth F, Jacobi H, Paap B, Vielhaber S, Machts J, Schols L, Synofzik M, Sturm M, Tallaksen C, Wedding IM, Boesch S, Eigentler A, van de Warrenburg B, van Gaalen J, Kamm C, Dudesek A, Kang JS, Timmann D, Silvestri G, Masciullo M, Klopstock T, Neuhofer C, Ganos C, Filla A, Bauer P, Tezenas du Montcel S, Klockgether T (2017) Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology 89:1043\u20131049","journal-title":"Neurology"},{"key":"8893_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature22044","volume":"544","author":"DR Scoles","year":"2017","unstructured":"Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM (2017) Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544:362\u2013366","journal-title":"Nature"},{"key":"8893_CR3","doi-asserted-by":"publisher","first-page":"R5364","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum Mol Genet 25:R53\u2013R64","journal-title":"Hum Mol Genet"},{"key":"8893_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrn.2017.92","volume":"18","author":"HL Paulson","year":"2017","unstructured":"Paulson HL, Shakkottai VG, Clark HB, Orr HT (2017) Polyglutamine spinocerebellar ataxias\u2014from genes to potential treatments. Nat Rev Neurosci 18:613\u2013626","journal-title":"Nat Rev Neurosci"},{"key":"8893_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC (2017) Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol Ther Nucleic Acids 8:232\u2013242","journal-title":"Mol Ther Nucleic Acids"},{"key":"8893_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2015-312972","volume":"87","author":"C Wilke","year":"2016","unstructured":"Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, Maia L, Maetzler W, Kuhle J, Synofzik M (2016) Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry 87:1270\u20131272","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8893_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56\u201366","journal-title":"Neuron"},{"key":"8893_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91:1\u20133","journal-title":"Neuron"},{"key":"8893_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acn3.212","volume":"2","author":"RA Menke","year":"2015","unstructured":"Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, Turner MR (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2:748\u2013755","journal-title":"Ann Clin Transl Neurol"},{"key":"8893_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83:1945\u20131953","journal-title":"Neurology"},{"key":"8893_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, Liman V, Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54:1655\u20131661","journal-title":"Clin Chem Lab Med"},{"key":"8893_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J, Swiss Multiple Sclerosis Cohort Study G (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857\u2013870","journal-title":"Ann Neurol"},{"key":"8893_CR13","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.0000000000004645","volume":"89","author":"T Gattringer","year":"2017","unstructured":"Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Grobke S, Voortman M, Pirpamer L, Hofer E, Ropele S, Schmidt R, Kuhle J, Fazekas F, Khalil M (2017) Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 89:2108\u20132114","journal-title":"Neurology"},{"key":"8893_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670\u2013676","journal-title":"Neurology"},{"key":"8893_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000227891.25592.8c","volume":"67","author":"WF Abdo","year":"2006","unstructured":"Abdo WF, van de Warrenburg BP, Munneke M, van Geel WJ, Bloem BR, Kremer HP, Verbeek MM (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67:474\u2013479","journal-title":"Neurology"},{"key":"8893_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang A-G (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149\u20131160","journal-title":"Behav Res Methods"},{"key":"8893_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717\u20131720","journal-title":"Neurology"},{"key":"8893_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12311-015-0686-4","volume":"15","author":"M Matsushima","year":"2016","unstructured":"Matsushima M, Yabe I, Oba K, Sakushima K, Mito Y, Takei A, Houzen H, Tsuzaka K, Yoshida K, Maruo Y, Sasaki H (2016) Comparison of different symptom assessment scales for multiple system atrophy. Cerebellum 15:190\u2013200","journal-title":"Cerebellum"},{"key":"8893_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930\u2013937","journal-title":"Neurology"},{"key":"8893_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2015.03.041","volume":"352","author":"W Sako","year":"2015","unstructured":"Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson\u2019s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352:84\u201387","journal-title":"J Neurol Sci"},{"key":"8893_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","volume":"77","author":"H Jacobi","year":"2011","unstructured":"Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, Durr A, Marelli C, Globas C, Linnemann C, Schols L, Rakowicz M, Rola R, Zdzienicka E, Schmitz-Hubsch T, Fancellu R, Mariotti C, Tomasello C, Baliko L, Melegh B, Filla A, Rinaldi C, van de Warrenburg BP, Verstappen CC, Szymanski S, Berciano J, Infante J, Timmann D, Boesch S, Hering S, Depondt C, Pandolfo M, Kang JS, Ratzka S, Schulz J, Tezenas du Montcel S, Klockgether T (2011) The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 77:1035\u20131041","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8893-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:40:13Z","timestamp":1557258013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8893-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["8893"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8893-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733200526.793552240","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JK\u2019s institution (University Hospital Basel) received in the last 3\u00a0years and used exclusively for research support: consulting fees from Novartis, Protagen AG; speaker fees from the Swiss MS Society, Biogen, Novartis, Roche, Genzyme; travel expenses from Merck Serono, Novartis; grants from ECTRIMS Research Fellowship Programme, University of Basel, Swiss MS Society, Swiss National Research Foundation, Bayer (Switzerland) AG, Genzyme, Novartis. MS received speaker\u2019s honoraria and research support from Actelion Pharmaceuticals, unrelated to the current project and manuscript. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The university\u2019s ethics committee approved the study; the methods were carried out in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statements"}},{"value":"All the subjects gave a written informed consent prior to participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The datasets analysed in the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}